Novo Nordisk A/S ADR (NVO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2023 | 12-2022 | 12-2021 | 12-2020 | 12-2019 | |
| Sales | 33,724,300 | 25,056,690 | 22,401,280 | 19,448,130 | 18,290,950 |
| Cost of Goods | 5,193,078 | 4,028,237 | 3,763,988 | 3,206,782 | 3,011,191 |
| Gross Profit | 28,531,220 | 21,028,450 | 18,637,290 | 16,241,340 | 15,279,760 |
| Operating Expenses | 13,637,550 | 10,435,730 | 9,308,020 | 7,950,020 | 7,412,750 |
| Operating Income | 14,893,750 | 10,592,950 | 9,330,261 | 8,292,104 | 7,867,202 |
| Interest Expense | 122,694 | 847,618 | 389,954 | 401,997 | 598,851 |
| Other Income | 427,614 | 33,848 | 459,321 | 249,409 | 9,744 |
| Pre-tax Income | 15,198,670 | 9,779,180 | 9,399,628 | 8,139,516 | 7,278,095 |
| Income Tax | 3,047,893 | 1,916,839 | 1,801,489 | 1,683,974 | 1,439,340 |
| Net Income Continuous | 12,150,770 | 7,862,340 | 7,598,139 | 6,455,542 | 5,838,755 |
| Net Income | $12,150,770 | $7,862,340 | $7,598,139 | $6,455,542 | $5,838,755 |
| EPS Basic Total Ops | 2.71 | 1.74 | 1.65 | 1.38 | 1.23 |
| EPS Basic Continuous Ops | 2.71 | 1.74 | 1.65 | 1.38 | 1.23 |
| EPS Diluted Total Ops | 2.70 | 1.73 | 1.65 | 1.38 | 1.23 |
| EPS Diluted Continuous Ops | 2.70 | 1.73 | 1.65 | 1.38 | 1.23 |
| EPS Diluted Before Non-Recurring Items | 2.70 | 1.73 | 1.65 | 1.38 | 1.23 |
| EBITDA(a) | $16,260,510 | $11,635,410 | $10,288,840 | $9,173,462 | $8,715,786 |